-transparent.png){kind=logo}
With the recent cloning of a second gene coding for the prostaglandin endoperoxide (PGH) synthase (cyclooxygenase), it has become obvious that mammalian cells contain two related, but unique, isozymes of PGH synthase. Both of these isozymes catalyze the conversion of arachidonic acid to PGH2, leading to production of biologically active prostaglandins. Although the first of these isozymes, PGH synthase-1 (PGHS-1), has long been thought to be the primary and sole site of action of nonsteroidal antiinflammatory drugs (NSAIDs), it is now known that the second isozyme, PGH synthase-2 (PGHS-2), is also sensitive to NSAIDs. Cloning of complementary DNAs for murine PGHS-1 and PGHS-2 has permitted individual expression of these two isozymes in the cos-1 cell system and comparison of their relative inhibition by several common NSAIDs in vitro. These studies have demonstrated that the two mouse isozymes, PGHS-1 and PGHS-2, are pharmacologically distinct. PGHS-1 is a constitutively expressed enzyme that early observations indicate is the principal enzyme involved in producing prostaglandins that regulate cellular housekeeping functions, such as gastric cytoprotection, vascular homeostasis, and kidney function. In contrast, PGHS-2 appears only to be expressed in inflamed tissue or following exposure to growth factors, lymphokines, or other mediators of inflammation. Expression of PGHS-2 is inhibited by antiinflammatory glucocorticoids, lending further support to the hypothesis that this enzyme produces prostaglandins involved in inflammation. We have identified NSAIDs that preferentially inhibit murine PGHS-1 or PGHS-2 or inhibit both isozymes equally. The finding that the two isozymes can be differentially inhibited provides a possible mechanism for identifying safer, more effective NSAIDs. Screening for drugs that preferentially inhibit PGHS-2 may allow identification of NSAIDs that reduce inflammation, but spare renal and gastric prostaglandin synthesis, thus reducing the untoward side effects commonly associated with most NSAIDs. Thus far, nabumetone is the only NSAID identified that preferentially inhibits murine PGHS-2.
D L DeWitt, and
E A Meade, and
W L Smith
January 1999,
Orthopedic nursing,
D L DeWitt, and
E A Meade, and
W L Smith
October 1981,
Delaware medical journal,
D L DeWitt, and
E A Meade, and
W L Smith
October 1980,
The New England journal of medicine,
D L DeWitt, and
E A Meade, and
W L Smith
January 1991,
Annals of the New York Academy of Sciences,
D L DeWitt, and
E A Meade, and
W L Smith
January 2015,
Revista medica del Instituto Mexicano del Seguro Social,
D L DeWitt, and
E A Meade, and
W L Smith
December 1993,
Proceedings of the National Academy of Sciences of the United States of America,
D L DeWitt, and
E A Meade, and
W L Smith
July 2000,
Digestive diseases and sciences,
D L DeWitt, and
E A Meade, and
W L Smith
November 2002,
Current opinion in gastroenterology,
D L DeWitt, and
E A Meade, and
W L Smith
January 2006,
Vnitrni lekarstvi,
D L DeWitt, and
E A Meade, and
W L Smith
March 2004,
Anesthesiology,
